Berkshire Hathaway Reduces $338M in DaVita Inc. ($DVA)

Written by Opentrades · Published · Updated

Key Points

  • Berkshire Hathaway changed its DaVita Inc. ($DVA) stake by 5.2% last quarter, cutting to 30,100,585 shares worth $6.14 billion.
  • Wall Street's consensus rating on $DVA is Hold and an average price target of $193.71.
  • $DVA last traded around $203.83.

Berkshire Hathaway trimmed its position in DaVita Inc. ($DVA) by 5.2% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 30,100,585 shares of DaVita Inc. after selling 1,658,480 shares during the quarter. Berkshire Hathaway's holdings in DaVita Inc. were worth $6.14 billion as of its most recent filing.

DaVita Inc. ($DVA) Stock

Last price$203.83
Market cap$13.39B
P/E ratio20.12
Forward P/E12.14
PEG ratio0.65
Beta0.91
52-week low$101.00
52-week high$211.80
50-day MA$175.44
200-day MA$140.89
Current ratio1.42
Quick ratio1.28
Debt-to-equity12.61

DaVita Inc. Earnings

EPS (ttm)$10.37
Revenue (ttm)$13.84B
Revenue growth6.0%
Net margin5.6%
Return on equity81.0%
Next earningsMay 5, 2026

Analysts Set New Price Targets

ConsensusHold
Average target$193.71
High target$235.00
Low target$145.00
Analysts covering7

About DaVita Inc.

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.

ExchangeNYSE
SectorHealthcare
IndustryMedical Care Facilities
HeadquartersDenver, CO
CEOMr. Javier J. Rodriguez
Employees78,000
Websitehttps://www.davita.com

Related Filing Alerts

See Also

This instant news alert was generated by automated narrative technology and financial data from Opentrades and public regulatory filings. It is for informational purposes only and is not financial advice.